HLA-G Expression in Tumor Tissues and Soluble HLA-G Plasma Levels in Patients with Gastrointestinal Cancer

Document Type : Research Articles


1 Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran.

3 Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.


Background: Overexpression of human leukocyte antigen G (HLA-G) and increased plasma levels of soluble
HLA-G (sHLA-G) have been reported in different human malignancies, and are believed to be involved in tumor immune
evasion. Objectives: This study was designed to evaluate the expression of HLA-G in tumor tissues and the plasma
levels of sHLA-G in patients with gastrointestinal cancer, and to determine their associations with clinicopathological
factors. The link between Helicobacter pylori infection and increased HLA-G expression or sHLA-G levels was also
investigated in patients with gastric cancer. Methods: HLA-G expression was investigated in tumor tissues from 100
patients with gastric and colorectal adenocarcinoma using immunohistochemistry test, and plasma levels of sHLA-G
were measured in 82 patients with ELISA method. The presence of H. pylori genome was investigated in tumor
tissues from 25 patients with gastric cancer by PCR method. Results: HLA-G expression was observed in 43% of
colorectal cancers and 34.6% of gastric cancers, and was not related with any of the clinicopathological factors. There
was a significant correlation between increased sHLA-G level and stage I tumors. Eight of 25 (32%) gastric cancer
specimens were positive for H. pylori, of which 3 samples were positive for HLA-G. Soluble HLA-G levels were above
the cut-off value in all H. pylori-positive patients. Conclusion: Plasma levels of sHLA-G were significantly increased
in our patients with a sensitivity of 89% and a specificity of 62%. Soluble HLA-G level can be considered a useful
indicator for the early diagnosis of gastric and colorectal adenocarcinoma.


Main Subjects

Volume 19, Issue 10
October 2018
Pages 2731-2735
  • Receive Date: 02 July 2017
  • Revise Date: 13 September 2018
  • Accept Date: 02 September 2018
  • First Publish Date: 01 October 2018